Clinical trials: Contraceptive Methods
Contraception
Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear.
- Trial name
- NCT00196326
- Testing
- DR-1011
- Where
- 55 sites in United States
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Contraception
Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women
Purpose of the study is to investigate safety and contraceptive efficacy of an LNG-containing intravaginal ring.
- Trial name
- NCT02403401
- Testing
- Levonorgestrel (BAY98-7196)
- Where
- 100 sites in United States, Japan
- Volunteers
- 1,471 people
- Sponsor
- Bayer
Contraception
Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites
Influence of different application sites on the blood levels after administration of a fertility control patch
- Trial name
- NCT01083264
- Testing
- Gestodene/EE Patch (BAY86-5016)
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Bayer
Emergency Contraception
Safety and Efficacy of CDB-2914 for Emergency Contraception
The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.
- Trial name
- NCT00411684
- Testing
- CDB-2914
- Where
- 17 sites in United States
- Volunteers
- 1,623 people
- Sponsor
- HRA Pharma
Contraception
MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study
The study is designed as non interventional to observe the continuation rate and the patient satisfaction in women who have a LNG-IUS (Levonorgestrel releasing Intrauterine system) inserted for contraception over the period of 12…
- Trial name
- MIDAS (NCT01961375)
- Testing
- Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
- Where
- India
- Volunteers
- 600 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Contraception
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.
- Trial name
- NCT00245921
- Testing
- Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg
- Volunteers
- 2,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Contraception
The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol
This study will evaluate the effect of Annovera and tampon co-usage on the pharmacokinetics (PK) of segesterone acetate (SA) and ethinyl estradiol (EE).
- Trial name
- NCT04272008
- Testing
- Segesterone Acetate and Ethinyl Estradiol, Tampon
- Where
- 2 sites in United States, Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- TherapeuticsMD
Contraception
Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
A single-center, randomized, open-label, parallel-group, multi-arm, phase II clinical trial in healthy women aged 18 to 35 years who have a documented ovulatory cycle prior to randomization.
- Trial name
- NCT06048536
- Testing
- MR-130A-01 Transdermal patch
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Contraception
FemBloc® Permanent Contraception - Early Pivotal Trial
Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control).
- Trial name
- BLOC (NCT03433911)
- Testing
- FemBloc, Laparoscopic bilateral tubal sterilization
- Where
- 12 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Femasys Inc.
Contraception
JAYDESS Drug Utilization Study in Sweden
To describe characteristics (demographic, clinical, social) of first time users of Jaydess To estimate the duration of use of Jaydess To study switching patterns, e.g.
- Trial name
- NCT02349815
- Testing
- Levonorgestrel (Jaydess, Skyla, BAY86-5028)
- Where
- Sweden
- Volunteers
- 10,000 people
- Sponsor
- Bayer
Contraception
LCS16 vs. COC User Satisfaction and Tolerability Study
To evaluate user satisfaction in young nulliparous and parous women (18-29 years of age [inclusive]), using LCS16 compared to a COC over a period of 12 months.
- Trial name
- NCT03074045
- Testing
- Levonorgestrel (Kyleena, BAY86-5028), Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
- Where
- 9 sites in Russia
- Volunteers
- 145 people
- Sponsor
- Bayer
Contraception
Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study
This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel…
- Trial name
- NCT00528112
- Testing
- LCS12, LCS16
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 2,885 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Validation of Effectiveness on NaturalCycles Users
The goal of this observational study is to measure the effectiveness of the Natural Cycles digital birth control application at preventing pregnancy in sexually active women aged 18 to 35 with no known history of infertility.
- Trial name
- VENUS (NCT07566793)
- Testing
- Log daily intercourse information, Natural Cycles application
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Natural Cycles
Contraception
Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2
This is an open-label, multi-centre, comparative study in young, healthy, female volunteers of reproductive age. Primary objective: To investigate the effect of 2 dosages of estetrol combined with P1 or P2, on vaginal bleeding…
- Trial name
- FIESTA (NCT01221831)
- Where
- 10 sites in Finland
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Estetra
Contraception
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol.
- Trial name
- NCT01699022
- Testing
- Injection Cyclofem
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Contraception
A Multicentre, Prospective, Open-label, Non-comparative Study
As there are no recent studies conducted in Italy on the profile of this COC, the purpose of this study is to evaluate its efficacy and tolerability in a given subset of women residing in Italy that are in need of contraception.
- Trial name
- NCT06067256
- Testing
- Female Contraceptive
- Where
- Italy
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Contraception
FR01 and FR20 IUS (Intrauterine System) Wearing Study
The aim of the study is to evaluate two different placebo intrauterine systems, placebo FR01 and FR20 with different types of inserters, for wearing comfort, insertion/removal ease and pain compared to a placebo T-frame…
- Trial name
- NCT01595022
- Where
- 10 sites in Finland, Netherlands and 1 more
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.
Contraception
EU/LA Pearl Index Study - Transdermal Contraceptive Patch
The aim of the present study is to prove efficacy and safety of a new contraceptive patch.
- Trial name
- NCT00914693
- Testing
- Ethinylestradiol/Gestodene (BAY86-5016)
- Where
- 66 sites in Argentina, Australia and 6 more
- Volunteers
- 1,694 people
- Sponsor
- Bayer